(0.05%) 5 471.94 points
(0.05%) 39 133 points
(0.37%) 17 783 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.75%) $2 313.30
(0.23%) $28.94
(3.61%) $1 022.00
(0.29%) $0.936
(0.71%) $10.68
(0.45%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma...
Stats | |
---|---|
今日成交量 | 493 360 |
平均成交量 | 1.60M |
市值 | 909.84M |
EPS | $-0.240 ( Q1 | 2024-05-17 ) |
下一个收益日期 | ( $-0.190 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.83 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.23%) |
音量 相关性
Autolus Therapeutics PLC 相关性 - 货币/商品
Autolus Therapeutics PLC 财务报表
Annual | 2023 |
营收: | $1.70M |
毛利润: | $-4.87M (-286.63 %) |
EPS: | $-1.200 |
FY | 2023 |
营收: | $1.70M |
毛利润: | $-4.87M (-286.63 %) |
EPS: | $-1.200 |
FY | 2022 |
营收: | $6.19M |
毛利润: | $-131.03M (-2 115.37 %) |
EPS: | $-1.570 |
FY | 2021 |
营收: | $2.33M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.970 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Autolus Therapeutics PLC
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。